menu

Managing Toxicities Associated With Anti-CD30 Targeted Therapy in Pediatric and Adolescent Patients

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treating Pediatric High-Risk cHL: Optimizing Care, Reducing Adverse Effects

Managing Toxicities Associated With Anti-CD30 Targeted Therapy in Pediatric and Adolescent Patients

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program provides awareness of the frontline therapeutic options for pediatric patients. Though current treatments are efficacious, creating a greater understanding of optimizing care while minimizing long-term toxicity from chemotherapy and radiation is critical. This clinician educational program focuses on implementing anti-CD30 targeted therapies effectively to change the disease trajectory for pediatric high-risk cHL. It provides an understanding of the expected adverse event profile of the disease and the overlap with novel therapies as we start using these emerging strategies to maximize our outcomes for the patients.

     

    Don’t miss two additional resources that complement this program: an interactive primary treatment dosing guide; and a patient education handout. Click the Documents tab above to access.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including Pediatric Hematologists/Oncologists, Hematologists/Oncologists, Advanced Practice Professionals, Pediatric Oncology Nurses, Infusion Nurses, and Oncology Pharmacists involved in the management of patients with pediatric high-risk Classical Hodgkin Lymphoma (cHL).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Apply the latest evidence-based strategies in the frontline treatment of pediatric high-risk classical Hodgkin lymphoma
    • Employ effective multidisciplinary adverse effect management strategies to improve the integration of anti-CD30-based treatment regimens in practice
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

     

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Bradford Hoppe, MD, MPH, faculty for this educational event, has received consulting fees from Merck/COG. 

    Kara Kelly, MD, faculty for this educational event, has received research funding from Merck.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Seagen, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 4/28/2023 through 4/28/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule28 Mar 2024